RÉSUMÉ
Cytokine-primed neutrophils can undergo a nonapoptotic type of cell death using components of the necroptotic pathway, including receptor-interacting protein kinase-3 (RIPK3), mixed lineage kinase-like (MLKL) and NADPH oxidase. In this report, we provide evidence for a potential role of serine proteases in CD44-mediated necroptotic death of GM-CSF-primed human neutrophils. Specifically, we observed that several inhibitors known to block the enzymatic function of fibroblast activation protein-α (FAP-α) were able to block CD44-mediated reactive oxygen species production and cell death, but not FAS receptor-mediated apoptosis. To understand how FAP-α is involved in this nonapoptotic death pathway, we performed immunoblotting experiments in the presence and absence of inhibitors of RIPK3, MLKL, p38 MAPK, PI3K, and FAP-α. The results of these experiments suggested that FAP-α is active in parallel with RIPK3, MLKL, and p38 MAPK activation but proximal to PI3K and NADPH oxidase activation. Interestingly, neutrophils isolated from the joints of patients suffering from rheumatoid arthritis underwent a GM-CSF-independent necroptosis following CD44 ligation; this effect was also blocked by both FAP-α and MLKL inhibitors. Taken together, our evidence shows that the RIPK3-MLKL pathway activates NADPH oxidase but requires, in addition to p38 MAPK and PI3K, a serine protease activity, whereby FAP-α is the most likely candidate. Thus, FAP-α could be a potential drug target in neutrophilic inflammatory responses to avoid exaggerated nonapoptotic neutrophil death, leading to tissue damage.
Sujet(s)
Polyarthrite rhumatoïde/immunologie , Gelatinases/métabolisme , Protéines membranaires/métabolisme , Granulocytes neutrophiles/métabolisme , Protein kinases/métabolisme , Receptor-Interacting Protein Serine-Threonine Kinases/métabolisme , Serine endopeptidases/métabolisme , Cellules cultivées , Endopeptidases , Facteur de stimulation des colonies de granulocytes et de macrophages/métabolisme , Humains , Thérapie moléculaire ciblée , NADPH oxidase/métabolisme , Nécroptose , Activation des neutrophiles , Granulocytes neutrophiles/immunologie , Transduction du signal , Antigènes CD95/métabolismeRÉSUMÉ
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent BTK inhibitors is limited to oncology indications based on their suboptimal kinase selectivity. We describe the discovery and preclinical profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor. LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases. It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis. LOU064 is currently being tested in phase 2 clinical studies for chronic spontaneous urticaria and Sjoegren's syndrome.
Sujet(s)
Agammaglobulinaemia tyrosine kinase/antagonistes et inhibiteurs , Agammaglobulinaemia tyrosine kinase/métabolisme , Découverte de médicament/méthodes , Inhibiteurs de protéines kinases/métabolisme , Inhibiteurs de protéines kinases/pharmacologie , Agammaglobulinaemia tyrosine kinase/composition chimique , Animaux , Benzamides/composition chimique , Benzamides/métabolisme , Benzamides/pharmacologie , Composés hétérocycliques bicycliques/composition chimique , Composés hétérocycliques bicycliques/métabolisme , Composés hétérocycliques bicycliques/pharmacologie , Cristallographie aux rayons X/méthodes , Chiens , Relation dose-effet des médicaments , Femelle , Humains , Souris , Liaison aux protéines/physiologie , Inhibiteurs de protéines kinases/composition chimique , Structure secondaire des protéines , Structure tertiaire des protéines , Rats , Rats de lignée LEW , OvisRÉSUMÉ
Bruton's tyrosine kinase (BTK) is a member of the TEC kinase family and is selectively expressed in a subset of immune cells. It is a key regulator of antigen receptor signaling in B cells and of Fc receptor signaling in mast cells and macrophages. A BTK inhibitor will likely have a positive impact on autoimmune diseases which are caused by autoreactive B cells and immune-complex driven inflammation. We report the design, optimization, and characterization of potent and selective covalent BTK inhibitors. Starting from the selective reversible inhibitor 3 binding to an inactive conformation of BTK, we designed covalent irreversible compounds by attaching an electrophilic warhead to reach Cys481. The first prototype 4 covalently modified BTK and showed an excellent kinase selectivity including several Cys-containing kinases, validating the design concept. In addition, this compound blocked FcγR-mediated hypersensitivity in vivo. Optimization of whole blood potency and metabolic stability resulted in compounds such as 8, which maintained the excellent kinase selectivity and showed improved BTK occupancy in vivo.
RÉSUMÉ
Hdm2 (human MDM2, human double minuteâ 2 homologue) counteracts p53 function by direct binding to p53 and by ubiquitin-dependent p53 protein degradation. Activation of p53 by inhibitors of the p53-Hdm2 interaction is being pursued as a therapeutic strategy in p53 wild-type cancers. In addition, HdmX (human MDMX, human MDM4) was also identified as an important therapeutic target to efficiently reactivate p53, and it is likely that dual inhibition of Hdm2 and HdmX is beneficial. Herein we report four new X-ray structures for Hdm2 and five new X-ray structures for HdmX complexes, involving different classes of synthetic compounds (including the worldwide highest resolutions for Hdm2 and HdmX, at 1.13 and 1.20â Å, respectively). We also reveal the key additive 18-crown-ether, which we discovered to enable HdmX crystallization and show its stabilization of various Lys residues. In addition, we report the previously unpublished details of X-ray structure determinations for eight further Hdm2 complexes, including the clinical trial compounds NVP-CGM097 and NVP-HDM201. An analysis of all compound binding modes reveals new and deepened insight into the possible adaptations and structural states of Hdm2 (e.g., flip of F55, flip of Y67, reorientation of H96) and HdmX (e.g., flip of H55, dimer induction), enabling key binding interactions for different compound classes. To facilitate comparisons, we used the same numbering for Hdm2 (as in Q00987) and HdmX (as in O15151, but minus 1). Taken together, these structural insights should prove useful for the design and optimization of further selective and/or dual Hdm2/HdmX inhibitors.
Sujet(s)
Protéines du cycle cellulaire/métabolisme , Composés hétérocycliques/métabolisme , Protéines proto-oncogènes c-mdm2/métabolisme , Protéines proto-oncogènes/métabolisme , Sites de fixation , Protéines du cycle cellulaire/composition chimique , Cristallographie aux rayons X , Composés hétérocycliques/composition chimique , Humains , Liaison aux protéines , Protéines proto-oncogènes/composition chimique , Protéines proto-oncogènes c-mdm2/composition chimiqueRÉSUMÉ
Blocking the interaction between the p53 tumor suppressor and its regulatory protein MDM2 is a promising therapeutic concept under current investigation in oncology drug research. We report here the discovery of the first representatives of a new class of small molecule inhibitors of this protein-protein interaction: the dihydroisoquinolinones. Starting from an initial hit identified by virtual screening, a derivatization program has resulted in compound 11, a low nanomolar inhibitor of the p53-MDM2 interaction showing significant cellular activity. Initially based on a binding mode hypothesis, this effort was then guided by a X-ray co-crystal structure of MDM2 in complex with one of the synthesized analogs. The X-ray structure revealed an unprecedented binding mode for p53-MDM2 inhibitors.
Sujet(s)
Isoquinoléines/composition chimique , Isoquinoléines/pharmacologie , Cartes d'interactions protéiques/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-mdm2/métabolisme , Protéine p53 suppresseur de tumeur/métabolisme , Cristallographie aux rayons X , Humains , Simulation de docking moléculaire , Liaison aux protéines/effets des médicaments et des substances chimiques , Protéines proto-oncogènes c-mdm2/antagonistes et inhibiteurs , Relation structure-activité , Protéine p53 suppresseur de tumeur/antagonistes et inhibiteursRÉSUMÉ
As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.
Sujet(s)
Antinéoplasiques/synthèse chimique , Antinéoplasiques/pharmacologie , Isoquinoléines/synthèse chimique , Isoquinoléines/pharmacologie , Pipérazines/synthèse chimique , Pipérazines/pharmacologie , Protéines proto-oncogènes c-mdm2/antagonistes et inhibiteurs , Protéine p53 suppresseur de tumeur/génétique , Animaux , Antinéoplasiques/pharmacocinétique , Lignée cellulaire tumorale , Essais cliniques de phase I comme sujet , Découverte de médicament , Humains , Isoquinoléines/pharmacocinétique , Pipérazines/pharmacocinétique , Rats , Relation structure-activité , Tests d'activité antitumorale sur modèle de xénogreffeRÉSUMÉ
Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer types. In particular, several chromosomal rearrangements involving TRKA have been reported in colorectal, papillary thyroid, glioblastoma, melanoma, and lung tissue that are believed to be the key oncogenic driver in these tumors. By screening the Novartis compound collection, a novel imidazopyridazine TRK inhibitor was identified that served as a launching point for drug optimization. Structure guided drug design led to the identification of (R)-2-phenylpyrrolidine substituted imidazopyridazines as a series of potent, selective, orally bioavailable pan-TRK inhibitors achieving tumor regression in rats bearing KM12 xenografts. From this work the (R)-2-phenylpyrrolidine has emerged as an ideal moiety to incorporate in bicyclic TRK inhibitors by virtue of its shape complementarity to the hydrophobic pocket of TRKs.
RÉSUMÉ
Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy for the p53-HDM2 inhibitor NVP-CGM097, currently under evaluation in clinical trials. By intersecting high-throughput cell line sensitivity data with genomic data, we have identified a gene expression signature consisting of 13 up-regulated genes that predicts for sensitivity to NVP-CGM097 in both cell lines and in patient-derived tumor xenograft models. Interestingly, these 13 genes are known p53 downstream target genes, suggesting that the identified gene signature reflects the presence of at least a partially activated p53 pathway in NVP-CGM097-sensitive tumors. Together, our findings provide evidence for the use of this newly identified predictive gene signature to refine the selection of patients with wild-type p53 tumors and increase the likelihood of response to treatment with p53-HDM2 inhibitors, such as NVP-CGM097.
Sujet(s)
Marqueurs biologiques/métabolisme , Régulation de l'expression des gènes tumoraux/effets des médicaments et des substances chimiques , Isoquinoléines/pharmacologie , Tumeurs/traitement médicamenteux , Sélection de patients , Pipérazines/pharmacologie , Protéines proto-oncogènes c-mdm2/antagonistes et inhibiteurs , Protéine p53 suppresseur de tumeur/génétique , Lignée cellulaire tumorale , Transfert d'énergie par résonance de fluorescence , Analyse de profil d'expression de gènes , Humains , Séquençage par oligonucléotides en batterie , Protéines proto-oncogènes c-mdm2/métabolisme , Protéine p53 suppresseur de tumeur/métabolismeRÉSUMÉ
The G protein-coupled receptor EBI2 (Epstein-Barr virus-induced gene 2) is activated by 7α, 25-dihydroxycholesterol (7α25HC) and plays a role in T cell-dependant antibody response and B cell migration. Aberrant EBI2 signaling is implicated in a range of autoimmune disorders however its role in the CNS remains unknown. Here we characterize the functional role of EBI2 in GLIA cells using primary human astrocytes and EBI2 knockout animals. We find human and mouse astrocytes express EBI2 and the enzymes necessary for synthesis and degradation of 7α25HC. In astrocytes, EBI2 activation stimulates ERK phosphorylation, Ca(2+) signaling and induces cellular migration. These results, for the first time, demonstrate a role for EBI2 in astrocyte function and suggest that modulation of this receptor may be beneficial in neuroinflammatory disorders.
Sujet(s)
Astrocytes/métabolisme , Mouvement cellulaire/physiologie , Récepteurs couplés aux protéines G/métabolisme , Analyse de variance , Animaux , Animaux nouveau-nés , Aire sous la courbe , Signalisation calcique/physiologie , Différenciation cellulaire , Mouvement cellulaire/génétique , Cortex cérébral/cytologie , Cholestérol/pharmacocinétique , Extracellular Signal-Regulated MAP Kinases/métabolisme , Cytométrie en flux , Protéine gliofibrillaire acide/métabolisme , Humains , Souris , Souris de lignée C57BL , Souris knockout , Récepteurs couplés aux protéines G/antagonistes et inhibiteurs , Récepteurs couplés aux protéines G/génétique , Transduction du signal , TransfectionRÉSUMÉ
Oxysterols have recently been identified as natural ligands for a G protein-coupled receptor called EBI2 (aka GPR183) ( Nature 2011 , 475 , 524 ; 519 ). EBI2 is highly expressed in immune cells ( J. Biol. Chem. 2006 , 281 , 13199 ), and its activation has been shown to be critical for the adaptive immune response and has been genetically linked to autoimmune diseases such as type I diabetes ( Nature 2010 , 467 , 460 ). Here we describe the isolation of a potent small molecule antagonist for the EBI2 receptor. First, we identified a small molecule agonist NIBR51 (1), which enabled identification of inhibitors of receptor activation. One antagonist called NIBR127 (2) was used as a starting point for a medicinal chemistry campaign, which yielded NIBR189 (4m). This compound was extensively characterized in binding and various functional signaling assays. Furthermore, we have used 4m to block migration of a monocyte cell line called U937, suggesting a functional role of the oxysterol/EBI2 pathway in these immune cells.
Sujet(s)
Herpèsvirus humain de type 4 , Récepteurs couplés aux protéines G/antagonistes et inhibiteurs , Animaux , Cellules CHO , Calcium/métabolisme , Cricetulus , Humains , Mâle , Souris , Souris de lignée C57BL , Cellules U937RÉSUMÉ
Oxysterols such as 7 alpha, 25-dihydroxycholesterol (7α,25-OHC) are natural ligands for the Epstein-Barr virus (EBV)-induced gene 2 (EBI2, aka GPR183), a G protein-coupled receptor (GPCR) highly expressed in immune cells and required for adaptive immune responses. Activation of EBI2 by specific oxysterols leads to chemotaxis of B cells in lymphoid tissues. While the ligand gradient necessary for this critical process of the adaptive immune response is established by a stromal cells subset here we investigate the involvement of the oxysterol/EBI2 system in the innate immune response. First, we show that primary human macrophages express EBI2 and the enzymes needed for ligand production such as cholesterol 25-hydroxylase (CH25H), sterol 27-hydroxylase (CYP27A1), and oxysterol 7α-hydroxylase (CYP7B1). Furthermore, challenge of monocyte-derived macrophages with lipopolysaccharides (LPS) triggers a strong up-regulation of CH25H and CYP7B1 in comparison to a transient increase in EBI2 expression. Stimulation of EBI2 expressed on macrophages leads to calcium mobilization and to directed cell migration. Supernatants of LPS-stimulated macrophages are able to stimulate EBI2 signaling indicating that an induction of CH25H, CYP27A1, and CYP7B1 results in an enhanced production and release of oxysterols into the cellular environment. This is a study characterizing the oxysterol/EBI2 pathway in primary monocyte-derived macrophages. Given the crucial functional role of macrophages in the innate immune response these results encourage further exploration of a possible link to systemic autoimmunity.
Sujet(s)
Hydroxycholestérols/métabolisme , Macrophages/métabolisme , Récepteurs couplés aux protéines G/métabolisme , Calcium/métabolisme , Mouvement cellulaire , Cellules cultivées , Cholestanetriol 26-monooxygenase/génétique , Cholestanetriol 26-monooxygenase/métabolisme , Famille-7 de cytochromes P450 , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Humains , Hydroxycholestérols/immunologie , Lipopolysaccharides/pharmacologie , Macrophages/effets des médicaments et des substances chimiques , Macrophages/immunologie , Monocytes/métabolisme , Monocytes/physiologie , Récepteurs couplés aux protéines G/génétique , Transduction du signal , Steroid hydroxylases/génétique , Steroid hydroxylases/métabolismeRÉSUMÉ
The successful launches of dipeptidyl peptidase IV (DPP IV) inhibitors as oral anti-diabetics warrant and spur the further quest for additional chemical entities in this promising class of therapeutics. Numerous pharmaceutical companies have pursued their proprietary candidates towards the clinic, resulting in a large body of published chemical structures associated with DPP IV. Herein, we report the discovery of a novel chemotype for DPP IV inhibition based on the C-(1-aryl-cyclohexyl)-methylamine scaffold and its optimization to compounds which selectively inhibit DPP IV at low-nM potency and exhibit an excellent oral pharmacokinetic profile in the rat.
Sujet(s)
Dipeptidyl peptidase 4/métabolisme , Inhibiteurs de la dipeptidyl-peptidase IV/synthèse chimique , Inhibiteurs de la dipeptidyl-peptidase IV/pharmacocinétique , Découverte de médicament , Méthylamines/synthèse chimique , Méthylamines/pharmacocinétique , Adamantane/analogues et dérivés , Adamantane/composition chimique , Adamantane/pharmacologie , Administration par voie orale , Animaux , Cellules Caco-2 , Cristallographie aux rayons X , Cyclisation , Inhibiteurs de la dipeptidyl-peptidase IV/composition chimique , Inhibiteurs de la dipeptidyl-peptidase IV/pharmacologie , Activation enzymatique/effets des médicaments et des substances chimiques , Humains , Concentration inhibitrice 50 , Méthylamines/composition chimique , Méthylamines/pharmacologie , Structure moléculaire , Nitriles/composition chimique , Nitriles/pharmacologie , Pyrazines/composition chimique , Pyrazines/pharmacologie , Pyrrolidines/composition chimique , Pyrrolidines/pharmacologie , Rats , Phosphate de sitagliptine , Triazoles/composition chimique , Triazoles/pharmacologie , VildagliptineRÉSUMÉ
Epstein-Barr virus-induced gene 2 (EBI2, also known as GPR183) is a G-protein-coupled receptor that is required for humoral immune responses; polymorphisms in the receptor have been associated with inflammatory autoimmune diseases. The natural ligand for EBI2 has been unknown. Here we describe the identification of 7α,25-dihydroxycholesterol (also called 7α,25-OHC or 5-cholesten-3ß,7α,25-triol) as a potent and selective agonist of EBI2. Functional activation of human EBI2 by 7α,25-OHC and closely related oxysterols was verified by monitoring second messenger readouts and saturable, high-affinity radioligand binding. Furthermore, we find that 7α,25-OHC and closely related oxysterols act as chemoattractants for immune cells expressing EBI2 by directing cell migration in vitro and in vivo. A critical enzyme required for the generation of 7α,25-OHC is cholesterol 25-hydroxylase (CH25H). Similar to EBI2 receptor knockout mice, mice deficient in CH25H fail to position activated B cells within the spleen to the outer follicle and mount a reduced plasma cell response after an immune challenge. This demonstrates that CH25H generates EBI2 biological activity in vivo and indicates that the EBI2-oxysterol signalling pathway has an important role in the adaptive immune response.
Sujet(s)
Hydroxycholestérols/pharmacologie , Récepteurs de surface cellulaire/immunologie , Animaux , Production d'anticorps/immunologie , Lymphocytes B , Lignée cellulaire , Mouvement cellulaire/effets des médicaments et des substances chimiques , Analyse de profil d'expression de gènes , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Régulation de l'expression des gènes/immunologie , Humains , Hydroxycholestérols/composition chimique , Foie/composition chimique , Souris , Souris knockout , Récepteurs couplés aux protéines G , Ovis , Lymphocytes T/immunologieRÉSUMÉ
One of the benefits of beta-peptides as potential candidates for biological applications is their stability against common peptidases. Attempts have been made to rationalize this stability by altering the electron availability of a given amide carbonyl bond through the introduction of polar substituents at the alpha-position of a single beta-amino acid. Such beta-amino acids (beta-homoglycine, beta-homoalanine), containing one or two fluorine atoms or a hydroxy group in the alpha-position, were prepared in enantiopure form. A versatile method for preparing these alpha-fluoro-beta-amino acids by the homologation of appropriate alpha-amino acids and C-OH->C-F or C=O-->CF(2) substitution with DAST, is described. Consequently, a series of beta-peptides possessing an electronically modified residue at the N terminus or embedded within the chain was synthesized, and their proteolytic stability was investigated against a selection of enzymes. All ten beta-peptides tested were resilient to proteolysis. Introducing a polar, sterically undemanding group, into the alpha-position of beta-amino acids in a beta-peptide chain does not appear to facilitate localized or general enzymatic degradation.
Sujet(s)
Acides aminés/composition chimique , Fluor/composition chimique , Peptides/composition chimique , Ingénierie des protéines/méthodes , Enzymes/composition chimique , Enzymes/métabolisme , Peptides/synthèse chimique , Peptides/métabolismeRÉSUMÉ
The syntheses of four glyco-imidazoles, which are pentose-derivatives belonging to the D-series, as well as the syntheses of their L-enantiomers, are reported. Starting from the known linear xylo, lyxo, arabino, and ribo imidazolo-pentoses in both the L- and the D-series, intramolecular Walden inversion led to the corresponding arabino, ribo, xylo, and lyxo pyrrolidinopentoses in the D- and the L-series, respectively, protection and deprotection steps being unavoidable prerequisites. The structures and configurations of all eight pyrrolidinopentoses were determined unambiguously, by a combination of 1H/13C NMR spectroscopy, circular dichroism and [alpha](D) values, in conjunction with single-crystal X-ray diffraction analysis of the L-xylo stereoisomer. Examination of the inhibitory properties of these imidazolo-pyrrolidinoses against six commonly encountered glycosidases led to the conclusion that by and large the L-stereoisomers are inactive, whereas three out the four D-stereoisomers proved to be poor to moderate inhibitors. It appears therefore that the most basic N(1) atom is not located in an optimal topology to be protonated easily inside the enzyme's active site.